```text
Wiki Article
Abciximab (C7E3, 143653-53-6): A Research Reagent Overview
Abciximab, also identified as C7E3 or bearing the CAS number 143653-53-6, represents a valuable laboratory compound extensively employed in cardiovascular research . This antibody fragment specifically targets the glycoprotein IIb/IIIa receptor on platelets , blocking platelet aggregation . Consequently , it's often employed as a method to examine the mechanisms underlying thrombosis and to evaluate the efficacy of antiplatelet therapies. Supply is typically restricted to institutional settings.
```
Abciximab Drug Research: Utilizing The C7E3 Fragment and 143653-53-6 in Research Investigations
Ongoing research into abciximab, a platelet aggregation inhibitor, frequently employs the monoclonal antibody C7E3 and the substance identified as 143653-53-6. These tools are essential for examining abciximab's biological activity, determining its therapeutic effect in experimental conditions, and understanding potential indicators of patient outcome. Continued exploration leveraging these specific reagents is likely to provide valuable data for improving patient care related to cardiovascular disease.
```text
C7E3 abciximab, also known as c7e3fragment, is a GPIIb/IIIa receptor antagonist widely utilized in scientific research. Its primary application lies in platelet aggregation studies, allowing investigators to probe the mechanisms underlying thrombosis and hemostasis. Researchers employ this agent to investigate the role of platelet activation in various disease Recombinant abciximab models, including ischemia-reperfusion injury and inflammation. Beyond basic research, abciximab is increasingly used in developing novel antithrombotic therapies and evaluating their efficacy. Furthermore, studies exploring its potential to modulate vascular smooth muscle cell function and reduce intracranial bleeding are ongoing. The availability of c7e3 abciximab facilitates a deeper understanding of platelet-mediated processes and contributes to the advancement of translational medicine. }
```
```text
Exploring Research Avenues with Abciximab 143653-53-6 using C7E3
Recent work indicate that the drug (identified as 143653-53-6) offers significant research potential, particularly when combined with the antibody fragment. Preliminary observations indicated that this association could improve clinical outcomes in various heart-related contexts. Further investigation is directed on defining the exact mechanism of action between Abciximab and C7E3, involving analysis of blood clot aggregation and vascular protection.
- Current investigation work seek to refine administration approaches.
- Laboratory approaches are were applied to more confirm the theories.
- Patient studies will be necessary to fully determine therapeutic efficacy.
```
Abciximab (C7E3) for Research: Specifications and Specifications (143653-53-6)
Researchers needing abciximab for laboratory investigations should rigorously evaluate integrity and precise specifications . This product is typically provided as a lyophilized powder and detailed analytical data including identity by LC-MS, potency assays, and endotoxin level testing must be available. Verify the manufacturer's CoA clearly states defined limits for contaminants and conforms to established QC criteria .
Pharmaceutical-Grade Abciximab Details & Supply
Acquiring laboratory-grade Abciximab, specifically referencing the antibody C7E3 and identified by the catalog number 143653-53-6, requires thorough consideration of its manufacturer. This agent is commonly utilized in in vitro investigations , particularly those focused on platelet clumping and thrombosis . Available suppliers offer this reagent in varying quantities , typically ranging from mg to substantial wholesale supplies. Please suggest reviewing the certificate of testing to verify quality and applicability for your specific use . Furthermore , check the shelf life date before procuring to maintain ideal effectiveness.
- Standard Purity: >95%
- Storage Conditions: -20°C and controlled conditions
- Application : Platelet Clumping Inhibition Studies